The United Kingdom and the United States have reached a important bilateral deal that will ensure no tariffs on UK medicine shipments going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the NHS. This pledge ensures that duties on these crucial goods will be held at zero for a timeframe of 36 months.
This deal follows earlier warnings to significantly raise tariffs on branded pharmaceutical imports, with potential rates discussed as high as 100%.
"This agreement with the UK reinforces the international landscape for innovative medicines and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a statement declared.
Economic Impact
Medicines are one of the UK's most significant export categories to the US, which is easily the primary market for large British pharmaceutical firms.
Trade data indicate that in the 12 months to the end of last September, the UK sold medicines totaling billions to the US. This figure represented 17.4% of British export trade in that timeframe.
"This guarantee protects work, boosts investment and facilitates the UK to become a global hub for medical research," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall public funding on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds exceeded twenty percent.
Broader Context
This agreement takes place against a long-running row between the sector and the UK government over spending levels and NHS adoption.
These tensions were exacerbated by assertions that US patients were paying several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been pledged toward American operations.
One official stated that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the last ten years.
